Last reviewed · How we verify
Bupropion, Escitalopram
Bupropion and Escitalopram are marketed drugs developed by Ewha Womans University, with a key composition patent expiring in 2028. The primary strength of these drugs lies in their established market presence and well-documented efficacy. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Bupropion, Escitalopram |
|---|---|
| Sponsor | Ewha Womans University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (PHASE3)
- Treating Negative Affect in Low Back Pain Patients (PHASE2, PHASE3)
- Neurobiological and Genomic Predictors of Relapse in Depression
- The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. (PHASE3)
- Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression (PHASE2)
- Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder. (PHASE3)
- A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupropion, Escitalopram CI brief — competitive landscape report
- Bupropion, Escitalopram updates RSS · CI watch RSS
- Ewha Womans University portfolio CI